Clinical Trials Logo

Tularemia clinical trials

View clinical trials related to Tularemia.

Filter by:
  • None
  • Page 1

NCT ID: NCT05300425 Recruiting - Leptospirosis Clinical Trials

Seroprevalence of Leptospirosis in Val Müstair, Switzerland

Start date: March 3, 2022
Phase:
Study type: Observational

Human leptospirosis is a zoonotic disease caused by bacteria of the genus Leptospira. Due to its frequent inapparent course or mild severity with unspecific symptoms and limited availability of diagnostic laboratories the incidence of leptospirosis is likely to be underestimated. The hospital of Val Müstair is the major healthcare provider of a rural mountain valley in the canton of Graubünden/ Switzerland with approximately 1500 inhabitants. A relevant prevalence of Leptospira spp. antibodies in the population of the Val Müstair due to its geographic and social risk profile for Leptospira infection, namely the close contact of the population to both livestock and wildlife in agriculture and hunting is estimated. The aim of this study is to analyze the burden of this disease in order to evaluate the need of preventive measures. In addition, seroepidemiological data for the Hepatitis E virus (HEV) and for tularemia will be collected.

NCT ID: NCT03867162 Withdrawn - Tularemia Clinical Trials

FY15-14: Tularemia Vaccine Protocol (NDBR Lot 4)

NDBR
Start date: June 9, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and immunogenicity of the tularemia vaccine, live, attenuated, NDBR 101, Lot 4, and collect data on the incidence of occupational tularemia infection in vaccinated personnel.

NCT ID: NCT01150695 Completed - Tularaemia Clinical Trials

Phase II Tularemia Vaccine Comparison

Start date: September 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare 2 experimental vaccines that could provide protection from the disease, tularemia. This research will compare the ability of the vaccines to cause the body to develop an immune (protective) response and obtain more information on side effects of the vaccines. About 220 male and non-pregnant female volunteers 18 to 45 years will participate. Volunteers will be assigned to 1 of 2 vaccine groups by chance. About half of the volunteers will be placed in the DVC-LVS vaccine group and half of volunteers will be placed in the USAMRIID-LVS vaccine group. Additionally, both groups will receive an injection of placebo (inactive salt water). Study procedures include physical exam and blood and urine samples. Evaluation of the vaccination sites will be performed as well as blood samples to measure the body's response to the vaccine. Participants will be involved in the study for about 6 months.

NCT ID: NCT00787826 Enrolling by invitation - Tularemia Clinical Trials

Continued Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine

Start date: August 28, 2009
Phase: Phase 2
Study type: Interventional

This study is designed to determine the safety and immunogenicity of a Live Francisella tularensis Vaccine

NCT ID: NCT00584844 Completed - Tularemia Clinical Trials

Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine

Start date: October 2004
Phase: Phase 2
Study type: Interventional

This study is designed to determine the safety and immunogenicity of a Live Francisella tularensis Vaccine